Advances in Targeted Therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells (e.g. with traditional chemotherapy). Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy (and thus distinguished from chemotherapy, that is, cytotoxic therapy). However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

In the present book, twelve typical literatures about Targeted Therapy published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on Targeted Therapy. We hope this book can demonstrate advances in Targeted Therapy as well as give references to the researchers, students and other related people.

Sample Chapter(s)
Preface (141 KB)
Components of the Book:
  • Chapter 1
    Targeted therapy in melanoma
  • Chapter 2
    Determining Duration of HER2-Targeted Therapy Using Stem Cell Extinction Models
  • Chapter 3
    Do cancer biomarkers make targeted therapies cost-effective? A systematic review in metastatic colorectal cancer
  • Chapter 4
    Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review
  • Chapter 5
    Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
  • Chapter 6
    The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
  • Chapter 7
    Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
  • Chapter 8
    Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy
  • Chapter 9
    EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer
  • Chapter 10
    RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
  • Chapter 11
    Sequencing Targeted and Immune Therapy in BRAF Mutant Melanoma: Lessons Learned
  • Chapter 12
    Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
Readership: Students, academics, teachers and other people attending or interested in Targeted Therapy.
Paul M. D. Gape
School of Biomedical Engineering & Imaging Sciences, King’s College London, London SE1 7EP, UK

Michael K. Schultz
Departments of Radiology, Radiation Oncology, Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA 52242, USA

Robiya Joseph
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

and more...
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top